Skip to content
2000
Volume 5, Issue 4
  • ISSN: 1573-4021
  • E-ISSN: 1875-6506

Abstract

The endothelium is a rich source of biological mediators that serve to control blood flow, temper inflammation and maintain local homeostasis. Endothelium-derived nitric oxide (NO) is the prototype of these molecules and is critical in preventing the initiation and progression of vascular disease. Consistent with a central role for NO in vascular disease, disruptions in its production and/or bioavailability have been linked to hypertension, diabetes, hypercholesterolemia, obesity, aging, and smoking. Furthermore substrate and cofactor bioavailability, NOS isoform expression profiles and oxidative stress are crucial determinants as to whether homeostatic levels of NO are maintained in blood vessels. In addition to its direct actions, NO is an important modulator of other vasoregulatory pathways such as cyclooxygenase (COX)-derived eicosanoid production and angiotensin II generation by the renin-angiotensin system. Furthermore, NO may direct the selectivity of COX-2 inhibitors; a finding relevant to controversies associated with the use of these drugs. Herein, we examine pathways that are directly or indirectly modified by alterations in NO synthesis and that are targetable for the development of novel, effective and safe agents for the treatment of cardiovascular disease.

Loading

Article metrics loading...

/content/journals/chyr/10.2174/157340209789587726
2009-11-01
2025-11-04
Loading full text...

Full text loading...

/content/journals/chyr/10.2174/157340209789587726
Loading

  • Article Type:
    Research Article
Keyword(s): angiotensin; cyclooxygenase; nitric oxide; nitrotyrosine; prostaglandins; Vascular disease
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test